Barclays’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.94M | Sell |
122,838
-165,709
| -57% | -$9.66M | ﹤0.01% | 1634 |
|
|
2025
Q4 | $17.1M | Sell |
288,547
-566,041
| -66% | -$30.8M | ﹤0.01% | 1332 |
|
|
2025
Q3 | $46.3M | Buy |
854,588
+403,508
| +89% | +$23.1M | 0.01% | 811 |
|
|
2025
Q2 | $24.8M | Buy |
451,080
+177,265
| +65% | +$10.4M | 0.01% | 1012 |
|
|
2025
Q1 | $19.4M | Sell |
273,815
-55,051
| -17% | -$3.7M | 0.01% | 1051 |
|
|
2024
Q4 | $21.6M | Buy |
328,866
+41,275
| +14% | +$2.76M | 0.01% | 1075 |
|
|
2024
Q3 | $20.2M | Sell |
287,591
-830,789
| -74% | -$69.4M | 0.01% | 1059 |
|
|
2024
Q2 | $92.1M | Sell |
1,118,380
-4,136,140
| -79% | -$344M | 0.03% | 415 |
|
|
2024
Q1 | $459M | Sell |
5,254,520
-34,373
| -0.6% | -$3.08M | 0.16% | 110 |
|
|
2023
Q4 | $510M | Sell |
5,288,893
-284,264
| -5% | -$25.1M | 0.19% | 87 |
|
|
2023
Q3 | $493M | Buy |
5,573,157
+2,911,886
| +109% | +$259M | 0.31% | 58 |
|
|
2023
Q2 | $231M | Buy |
2,661,271
+1,056,445
| +66% | +$99.4M | 0.15% | 138 |
|
|
2023
Q1 | $156M | Sell |
1,604,826
-377,663
| -19% | -$39.2M | 0.07% | 182 |
|
|
2022
Q4 | $205M | Sell |
1,982,489
-270,314
| -12% | -$25.4M | 0.09% | 160 |
|
|
2022
Q3 | $191M | Buy |
2,252,803
+87,163
| +4% | +$7.76M | 0.21% | 103 |
|
|
2022
Q2 | $179M | Buy |
2,165,640
+2,001,395
| +1,219% | +$159M | 0.11% | 143 |
|
|
2022
Q1 | $12.7M | Sell |
164,245
-34,114
| -17% | -$2.85M | 0.01% | 834 |
|
|
2021
Q4 | $17.5M | Sell |
198,359
-10,771
| -5% | -$889K | 0.01% | 997 |
|
|
2021
Q3 | $16.2M | Buy |
209,130
+15,055
| +8% | +$1.19M | 0.01% | 976 |
|
|
2021
Q2 | $16.2M | Buy |
194,075
+9,219
| +5% | +$731K | 0.01% | 989 |
|
|
2021
Q1 | $14M | Sell |
184,856
-94,798
| -34% | -$7.74M | 0.01% | 944 |
|
|
2020
Q4 | $24.5M | Buy |
279,654
+56,826
| +26% | +$4.51M | 0.01% | 753 |
|
|
2020
Q3 | $17M | Sell |
222,828
-62,955
| -22% | -$6.37M | 0.01% | 812 |
|
|
2020
Q2 | $35.3M | Sell |
285,783
-13,284
| -4% | -$1.32M | 0.03% | 425 |
|
|
2020
Q1 | $25.3M | Sell |
299,067
-103,556
| -26% | -$8.92M | 0.02% | 547 |
|
|
2019
Q4 | $34M | Buy |
402,623
+170,459
| +73% | +$12.9M | 0.02% | 675 |
|
|
2019
Q3 | $15.6M | Sell |
232,164
-185,826
| -44% | -$14.3M | 0.01% | 1027 |
|
|
2019
Q2 | $35.8M | Buy |
417,990
+129,797
| +45% | +$11.1M | 0.02% | 624 |
|
|
2019
Q1 | $25.6M | Buy |
288,193
+32,717
| +13% | +$3.03M | 0.02% | 720 |
|
|
2018
Q4 | $21.8M | Sell |
255,476
-134,679
| -35% | -$12.8M | 0.02% | 708 |
|
|
2018
Q3 | $37.8M | Sell |
390,155
-105,106
| -21% | -$10.5M | 0.03% | 532 |
|
|
2018
Q2 | $46.7M | Buy |
495,261
+132,231
| +36% | +$11.6M | 0.04% | 384 |
|
|
2018
Q1 | $29.4M | Buy |
363,030
+7,445
| +2% | +$639K | 0.02% | 658 |
|
|
2017
Q4 | $31.7M | Buy |
355,585
+27,936
| +9% | +$2.43M | 0.03% | 580 |
|
|
2017
Q3 | $30.5M | Buy |
327,649
+9,857
| +3% | +$871K | 0.03% | 494 |
|
|
2017
Q2 | $28.9M | Buy |
317,792
+21,100
| +7% | +$1.92M | 0.03% | 451 |
|
|
2017
Q1 | $26M | Sell |
296,692
-7,632
| -3% | -$679K | 0.03% | 459 |
|
|
2016
Q4 | $25.2M | Buy |
304,324
+49,080
| +19% | +$4.22M | 0.03% | 501 |
|
|
2016
Q3 | $23.6M | Buy |
255,244
+35,012
| +16% | +$3.3M | 0.03% | 478 |
|
|
2016
Q2 | $17.1M | Sell |
220,232
-15,366
| -7% | -$1.31M | 0.02% | 583 |
|
|
2016
Q1 | $19.3M | Sell |
235,598
-21,540
| -8% | -$1.75M | 0.03% | 484 |
|
|
2015
Q4 | $26.7M | Sell |
257,138
-156,055
| -38% | -$16.3M | 0.03% | 468 |
|
|
2015
Q3 | $43.4M | Buy |
413,193
+241,852
| +141% | +$32.3M | 0.05% | 314 |
|
|
2015
Q2 | $23.3M | Buy |
171,341
+15,909
| +10% | +$1.97M | 0.03% | 585 |
|
|
2015
Q1 | $19.3M | Sell |
155,432
-108,411
| -41% | -$11.5M | 0.02% | 698 |
|
|
2014
Q4 | $23.7M | Sell |
263,843
-36,478
| -12% | -$3.03M | 0.02% | 671 |
|
|
2014
Q3 | $21.6M | Buy |
300,321
+34,851
| +13% | +$2.29M | 0.02% | 680 |
|
|
2014
Q2 | $16.5M | Buy |
265,470
+20,666
| +8% | +$1.25M | 0.02% | 810 |
|
|
2014
Q1 | $16.6M | Sell |
244,804
-362,562
| -60% | -$26.7M | 0.02% | 804 |
|
|
2013
Q4 | $42.5M | Buy |
607,366
+328,943
| +118% | +$22.3M | 0.04% | 397 |
|
|
2013
Q3 | $20M | Buy |
278,423
+126,947
| +84% | +$8.44M | 0.02% | 671 |
|
|
2013
Q2 | $8.44M | Buy |
+151,476
| New | +$9.44M | 0.01% | 1204 |
|
Other funds holding BMRN
VCM
VPM
Barclays's BMRN Position: Q1 2026 in Review
Barclays reduced its BioMarin Pharmaceuticals (BMRN) stake by 57% in Q1 2026, selling an estimated $9.66M and leaving 122,838 shares worth $6.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1634.
Barclays first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $510M in Q4 2023. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Barclays held 122,838 shares of BioMarin Pharmaceuticals worth $6.94M as of Q1 2026.
- Barclays sold 165,709 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $9.66M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1634 holding.
- Barclays first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's BioMarin Pharmaceuticals position peaked at $510M in Q4 2023.
- 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.